共 40 条
- [31] Evaluation of pharmacological intervention using a deep learning approach for histopathological scoring in a diet-induced obese and biopsy-confirmed mouse model of NASH with fibrosisJOURNAL OF HEPATOLOGY, 2020, 73 : S682 - S682Overgaard, AgneteSalinas, Casper G.Eschen, ChristianFeigh, MichaelOro, DeniseVeidal, Sanne
- [32] Comparative effects of liraglutide, elafibranor and obeticholic acid on NAFLD activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed NASHJOURNAL OF HEPATOLOGY, 2017, 66 (01) : S599 - S600Feigh, M.Tolbol, K. S.Kristiansen, M. B.Veidal, S. S.Fensholdt, L. D.Vrang, N.
- [33] MET409, a potent, non-bile acid sustained FXR agonist, improves NAFLD activity score and exerts anti-fibrotic effects in a diet-induced obese mouse model of biopsy-confirmed fibrosing NASHJOURNAL OF HEPATOLOGY, 2020, 73 : S682 - S683Veidal, SanneFeigh, MichaelTolbol, KirstineSmith, NicholasWagner, Brandee
- [34] DIETARY INTERVENTION IMPROVES INTESTINAL PERMEABILITY AND REDUCES COLON FIBRO-INFLAMMATION IN THE GAN DIET-INDUCED OBESE AND BIOPSY-CONFIRMED MOUSE MODEL OF MASHHEPATOLOGY, 2024, 80 : S782 - S783Pors, SusanneNohr-Meldgaard, JacobVoldum-Clausen, KristofferSarvari, Anitta KingaJagadeesan, SakthiAlmholt, KasperPetersen, Nataliade la Cour, Charlotta DornonvilleJorgensen, Sebastian BeckHansen, HenrikFeigh, Michael
- [35] Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves non-alcoholic steatohepatitis (NASH) in a GAN diet-induced and biopsy-confirmed mouse modelJOURNAL OF HEPATOLOGY, 2023, 78 : S763 - S764Jones, ChristopherNielsen, Malte H.Oro, DeniseFeigh, MichaelTeng, XiaoLie, AnthonyHo, GideonJasper, Jeffrey
- [36] NIS2-MICE, AN ADAPTATION OF THE CLINICAL NIS2+™ DIAGNOSTIC TEST FOR THE DETECTION OF NAS ≥ 4 & F ≥ 2 IN GAN DIET-INDUCED OBESE AND BIOPSY-CONFIRMED MOUSE MODEL OF NASH WITH ADVANCED FIBROSISHEPATOLOGY, 2023, 78 : S851 - S852Hajji, YacineDelecroix, ElodieMagnanensi, JeremyMajd, ZouherLevy, AudreyNielsen, Malte HaslePors, Susanne E.Rosenquist, ChristianFeigh, Michael
- [37] Effect of seladelpar and CB-0406 combination therapy on obesity, liver fibrosis and steatosis in a diet-induced obese (DIO) mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosisJOURNAL OF HEPATOLOGY, 2021, 75 : S596 - S597Choi, Yun-JungStebbins, JeffreyCable, EdSong, JiangaoJohnson, JeffMcWherter, Charles
- [38] A3907, A NOVEL INHIBITOR OF BILE ACID TRANSPORT IN THE INTESTINE AND KIDNEY, IMPROVES MARKERS OF METABOLIC AND HEPATIC PATHOLOGY, AND REDUCES NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE AND FIBROSIS STAGE IN A DIET-INDUCED AND BIOPSY-CONFIRMED MOUSE MODEL OF NONALCOHOLIC STEATOHEPATITISHEPATOLOGY, 2020, 72 : 315A - 316AAkerblad, PeterLundin, PalFeigh, MichaelNohr-Meldgaard, JacobHorn, PatrickMattsson, Jan P.Gillberg, Per-GoranSanyal, Arun J.
- [39] ID119031166, A NOVEL POTENT NON-BILE ACID FXR AGONIST, IMPROVES NASH AND LIVER FIBROSIS WITHOUT PLASMA LDL- C ELEVATION IN A DIET-INDUCED OBESE NASH HAMSTER MODELHEPATOLOGY, 2022, 76 : S611 - S611Moon, An-NaLee, YoonsukSong, Dong--KeunBriand, Francois
- [40] YH25724, a novel long-acting GLP-1/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitisJOURNAL OF HEPATOLOGY, 2017, 66 (01) : S16 - S17Hong, H. N.Kim, J. H.Choi, H. H.Kim, D.Kim, T. W.Tolbol, K. S.Feigh, M.Illemann, M.Rigbolt, K.Vrang, N.Kim, J. G.